Long-term benefits of omalizumab in a patient with severe non-allergic asthma

Allergy, Asthma and Clinical Immunology

Volumn 7, Issue 1, 2011, Pages

  Menzella, Francesco ^a   Piro, Roberto ^a   Facciolongo, Nicola ^a   Castagnetti, Claudia ^a   Simonazzi, Anna ^a   Zucchi, Luigi ^a  

^a Santa Maria Nuova Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; FORMOTEROL; IMMUNOGLOBULIN E; OMALIZUMAB; PREDNISONE; SALBUTAMOL; TIOTROPIUM BROMIDE;

ADULT; ARTICLE; ASTHMA; CASE REPORT; COMORBIDITY; CORTICOSTEROID THERAPY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG EFFICACY; FOLLOW UP; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MALE; QUALITY OF LIFE; TREATMENT DURATION;

EID: 80052268492     PISSN: 17101484     EISSN: 17101492     Source Type: Journal    
DOI: 10.1186/1710-1492-7-9     Document Type: Article

References (18)

1. National Heart, and Blood Institute Morbidity and mortality: 2002. 2002, Bethesda (MD) National Heart, Lung, and Blood Institute, National Heart, and Blood Institute.
2. European Lung White Book The first comprehensive survey on respiratory health in Europe. European Respiratory Society 2003, 16-25. Sheffield: ERSJ, Loddenkemper R, Gibson GJ, Sybille Y, European Lung White Book.
3. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60(3):309-16. 10.1111/j.1398-9995.2004.00772.x, 15679715.
4. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab versus placebo ad add on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011, 139(1):28-35. 10.1378/chest.10-1194, 20688929.
5. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2006, (2):CD003559.
6. European Medicine Agency (EMA)- Xolair. , http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000606/human_med_001162.jsp&murl=menus/medicines/medicines.jsp&jsenabled=true
7. GINA Global Strategy for Asthma Management and Prevention, 2006 NHI Publications No 02-3659. GINA update 2009, , http://www.ginasthma.org
8. Juniper EF, Guyatt GH, Ferrie PJ, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in asthma. Am Rev Respir Dis 1993, 147:832-8.
9. Lloyd A, Turk F, Leighton T, Canonica GW. Psychometric evaluation of Global Evaluation of Treatment Effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. Journal of Medical Economics 2007, 10(3):285-296.
10. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, Lecomte P, Hermans C, MacDonald K, Song M, Abraham I. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009, 103(11):1633-42. 10.1016/j.rmed.2009.06.014, 19619998.
11. Van den Berge M, Pauw RG, de Monchy JGR, van Minnen CA, Postma DS, Kerstjens HA. Beneficial effects of treatment with anti-IgE antibodies (omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest 2011, 139:190-193. 10.1378/chest.10-0128, 21208879.
12. Humbert M, Durham SR, Kimmitt P, Powell N, Assoufi B, Pfister R, Menz G, Kay AB, Corrigan CJ. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and non atopic subjects with asthma. J Allergy Clin Immunol 1997, 99(5):657-665. 10.1016/S0091-6749(97)70028-9, 9155833.
13. Beeh KM, Ksoll M, Buhl R. Elevation of total serum immunoglobulin E is associated with asthma in non allergic individuals. Eur Respir J 2000, 16(4):609-614. 10.1034/j.1399-3003.2000.16d07.x, 11106200.
14. Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005, 35:408-416. 10.1111/j.1365-2222.2005.02191.x, 15836747.
15. MacGlashan DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM. Down-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997, 158:1438-45.
16. Berger P, Scotto-Gomez E, Molimard M, Marthan R, Le Gros V, Tunon-de-Lara JM. Omalizumab decreases non-specific airway hyperresponsiveness. Allergy 2007, 62:154-161.
17. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2006, 63:548-61. 2000760, 17096680.
18. Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods 2005, 303:81-91. 10.1016/j.jim.2005.06.008, 16045925.